Summary. The generation of smooth aromatic-dependent Salmonella serotype Bovismorbificans (Group C2,06, 8) from a smooth wild-type parent strain by transduction with phage P 1, and conjugation with Salmonella serotype Typhimurium carrying F'-8gal is described. The smooth aromatic-dependent S. serotype Bovismorbificans was non-lethal for mice at an oral challenge dose of 2 x lo9 cfu (equivalent to 200 LD50 of the parent, wild-type strain). The safety of the auxotrophic mutant was further substantiated by comparing its multiplication kinetics in vivo with that of its virulent parent organisms. Mice immunised with live, smooth aromatic-dependent S. serotype Bovismorbificans by either the oral or intraperitoneal (i.p.) route were protected against oral challenge with virulent S. serotype Bovismorbificans; the degree of protection was significantly better (p < 0-05) at a challenge dose of 100 or 200 LD50 in mice receiving two rather than one vaccination. In contrast, mice immunised with three doses of the formalin-killed virulent, parent organisms by the i.p. route were not protected, in spite of high antibody titres. Only those mice immunised with the live, smooth aromatic-dependent S. serotype Bovismorbificans i.p. developed significant (p < 0.014.05) delayed-type hypersensitivity.
Introduction
Salmonellosis of ruminant animals is recognised as an important disease in most countries and causes serious economic losses, particularly in animals subjected to stressful conditions, such as those encountered during shipping over long distances1-* or intensively-managed livestock enterprises. Furthermore, it constitutes a serious public health hazard not only for the consumers of meat and meat products but also for the worker associated with the handling of these products such as abattoir emp10yees.~~ Although a wide variety of Salmonella serotypes has been reported from outbreaks of clinical salmonellosis, most episodes can be attributed to a cluster of selected serotypes. The most common isolates from cases of salmonellosis in cattle in Australia, in order of frequency, are S. serotypes Dublin, Typhimurium, and Bovismorbificans. In sheep, they are S. serotypes Typhimurium, Bovismorbificans and Havana. Our aim is to develop a composite salmonella vaccine containing aromatic-dependent derivatives of the above-mentioned pathogens and to evaluate its efficacy in reducing the mortality of sheep during transit over long distances. Previously we reported that sheep immunised with S. serotype Typhimurium aroA by either the oral or intramuscular route were highly protected against oral challenge with virulent organisms. 6 In this communication, we describe the manipulation of virulent S. serotype Bovismorbificans to aromatic-dependence and the vaccine potential of the S. serotype Bovismorbificans aroA thus generated in experimental murine salmonellosis as a model system in the first instance.
Materials and methods

Bacterial strains and phage lysates
Virulent S. serotype Bovismorbificans strain CS400/ SL5747 used in this investigation was isolated from a dead sheep. Other bacterial strains and phage lysates used in the generation of S. serotype Bovismorbificans aroA are shown in table I. The virulent parent strain and derivatives with mutation in the aroA gene were maintained as cultures from Brain Heart Infusion Broth (BHI) in glycerol at -70°C in a Biofreezer. Derivatives with mutations in the gal operon were characterised by determining the ability of mutant organisms to ferment galactose in MacConkey's agar base with D-galactose 0.5% and were grown in BHI with D-galactose for preservation at -70°C.
Generation of aromatic-dependent S. serotype Bovismorbificans
Various steps used in the generation of aromaticdependent S. serotype Bovismorbificans are shown in table I and are discussed in the Results section.
Determination of LD5O
The LD50 of the virulent S. serotype Bovismorbificans strain CS4OO/SL5747 was determined in BALB/c mice as described el~ewhere.~
Immunisation and challenge experiments
BALB/c, female mice (6-8 weeks old) were immunised with S. serotype Bovismorbificans aroA (CS405/ SL5794) either orally (one or two doses of 10" cfu/ mouse administered 7 days apart) or intraperitoneally (i.p.) (one dose of lo5 cfu/mouse or two doses of 10' and lo6 cfu administered 7 days apart). Additional groups of mice were immunised i.p. with formalinkilled S. serotype Bovismorbificans (three doses of lo7, 10' and lo9 cfu given at intervals of 7 days). All immunising doses were prepared by washing bacteria grown in BHI with sterile physiological saline and resuspension in the same diluent so that the total cfu to be administered was contained in a total volume of 0.5 ml. All mice (including unimmunised control mice) were challenged at 4 weeks post-immunisation with 20, 100 or 200 LD50 of virulent S. serotype Bovismorbificans (CS4OO/SL5747) by gavage with 0.5 ml of a culture grown in BHI with shaking at 37°C for 18 h and after adjustment of pH to 8.5. Mice were observed for 15 days after challenge and mortality was recorded. The number of mice in each group was 8-18.
Determination of multiplication of S . serotype Bovismorbificans aroA in vivo
The kinetics of survival of S. serotype Bovismorbificans aroA (CS405/SL5794) in mice were determined after inoculation by the i.p. (1 x lo5 cfu/mouse) or oral (5 x 10' cfu/mouse) route, over a period of 27 days after inoculation. S. serotype Bovismorbificans aroA were enumerated in liver, spleen, mesenteric lymph nodes (MLN) and intestine. Organs were homogenised with a Colworth Stomacher 400, sterile physiological saline (1.0 ml) was added and the homogenate was spread-plated for viable counts on BHI agar, with the exception of intestine samples for which Xylose Lysine Deoxycholate Medium (XLD) was used.
Immunological procedures
Antibody titres were determined by an enzymelinked immunosorbent assay.' Antigen (100 pg of protein) used for coating the ELISA plates (M129B, Dynatech) was prepared by ultrasonication of virulent S. serotype Bovismorbificans followed by centrifugation at 27 000 g to remove the cell debris. The ELISA titres were expressed as end-point antibody titres. The cut-off point was determined by an average of the optical densities at 405 nm for four antigen-free wells, with a high activity mouse-specific anti-S. serotype Bovismorbificans serum used at a dilution identical with the starting dilution of individual test samples.
ELISA titres were the sample dilutions determined by interpolation from the cut-off point.
Cutaneous hypersensitivity was measured by injecting the ultrasonicated antigen preparation described above (10 pg of protein in 5 pl of saline) into the foot pads of four mice and measuring their thickness with vernier calipers 48 h after inoculation. Cutaneous hypersensitivity was calculated as the mean increase in the foot-pad thickness (mm) after antigen injection in one hind foot minus that obtained after injection of saline in the other hind foot, measured 48 h after injection.
Statistical analyses
The significance of differences between mean log,,-transformed values for ELISA titres and hypersensitivity measurements was determined by Student's t test. Significance of protection in the mouse immunisation and challenge experiments was assessed by Fisher's Exact test.
Results
Generation of aromatic-dependent S. serotype Bovismorb$cans aroA
The wild-type strain of S. serotype Bovismorbificans, CS4OO/SL5747, was prototrophic, smooth (as indicated by resistance to rough-specific phages and by reaction with Salmonella 0 6,8 serum) and sensitive to Felix 0 phage; it was resistant to tetracycline. Salmonella of 0 groups other than A, B and D do not adsorb phage P22 which, therefore, cannot be used to transduce genes to or from such strains. Another general transducing phage, P 1, is, generally, ineffective on smooth Salmonella strains but active on strains with the mutation galE, because when grown on medium not supplemented with galactose they make "rough" LPS of type Rc (galactose-deficient), appropriate for adsorption of phage PI .' Galactose-negative (non-fermenting) mutants of the wild-type S. serotype Bovismorbificans strain were, therefore, isolated by selection for ability to grow on defined medium containing 2-deoxygalactose, which inhibits the growth of galactose-positive strains. Two of 20 such mutants tested were resistant to Felix 0 phage (indicating an LPS core defect) and sensitive to phage C21 which, like phage P1, acts efficiently on strains making type Rc LPS. These two mutants were sensitive also to rough-specific phages 6SR and Br60. The presence of galactose (plus glucose, to prevent galactose toxicity) in the medium used for testing phage sensitivities restored the phage sensitivity pattern of the wild-type parent strain, indicating loss of galE function but retention of galK and galT functions, so that exogenous galactose could be used for synthesis of UDP galactose, the precursor of the galactose units of LPS. One of the two galE mutants, CS40 1 /SL5750, was plated on autoclaved chloramphenicol/fusaric-acid medium' which impedes the growth of tetracycline-resistant Salmonella and Escherichia coli strains. Nine of 10 resistant mutants from this selection were found to be tetracycline-sensitive. One of them, CS402/SL5752, was treated with phage PI grown on an S. serotype Typhimurium strain, SL2328, which is galE and has a transposon-generated non-reverting mutation at aroA and an adjacent silent TnlO insertion, zbj-903 : : TnlO. Selection was made for tetracycline resistance. One of 34 tetracyclineresistant colonies tested was found to be aromaticdependent by co-transduction of aroA of the donor with its TnlO insertion. This transductant, CS403/ SL5780, had the same phage-sensitivity pattern as its parent, which showed that it still had the galE mutation, but its phage sensitivities were not altered when tested on galactose-supplemented medium. This probably indicates that it had lost galK or galT functions, or both, by a second mutation affecting the gal operon. As tetracycline resistance is not desirable in a live vaccine strain, a tetracycline-sensitive mutant, CS404/SL5758, was next isolated from CS403/SL5780 by the same method as before. Finally, to restore wildtype LPS character (smooth), strain CS404/SL5780 was given an F' factor, F'8, which includes the gal + operon of E. coli, by a conjugational cross with a S. serotype Typhimurium strain carrying this plasmid. A galactose-positive transconjugant, now smooth by the criterion of phage sensitivity pattern and 0-antigen character and still aromatic-dependent, was labelled CS405/SL5794. This strain was employed as a live vaccine in the trials. No reversion to aromaticindependence has been detected in strain CS405/ SL5794, as was to be expected since its transposongenerated aroA mutation, originally used to construct a S. serotype Typhimurium live vaccine strain, SL1479, has given no revertants in extensive trials of that strain.
Strain CS405 did not produce galactose-negative segregants at a rate detectable by streaking broth cultures on MacConkey agar base with added galactose, indicating either a fairly stable maintenance of the F' factor in this strain or, less probably, recombination of the wild-type gal' (of E . coli origin) of the F' factor with the mutant gal region of the salmonella chromosome.
In-vivo safety of various derivatives of S . serotype Bovismorbificans in mice
The oral LD50 of the parent virulent S. serotype Bovismorbificans (CS4OO/SL5747) was calculated to be 1 x lo7 cfu. As can be seen from table 11, a significant percentage of mice survived when challenged with 200 LD50 dose-equivalents of that calculated for the wild-type S. serotype Bovismorbificans, i.e., 2 x lo9 cfu of the galE (CS402/SL5752), galEgalK and/or galT, aroA (CS404/SL5785) or aroA Gal' (CS405/SL5794) smooth derivatives of S. serotype Bovismorbificans. The safety of S. serotype Bovismorbificans aroA (CS405/SL5794) in vivo was further substantiated by comparing its multiplication kinetics in vivo with that of its virulent parent when administered by oral or i.p.
routes. As shown in table 111, S. serotype Bovismorbificans aroA Gal' (CS405/SL5794) was present in the liver, spleen, MLN and intestine (only in small numbers) regardless of the route of administration. By day 27 after oral administration, the mutant organisms were detectable in the intestine (in small numbers) but not in liver, spleen or MLN. On the other hand, when the organisms were administered by the i.p. route, the mutant aroA organisms were detectable in the spleen and MLN (not liver or intestine) of one out of three mice, but only by enrichment cultures. When mice were inoculated with the virulent parent organisms (CS4OO/SL5747) by the oral route, the organisms were detectable by direct plating on day 1 in the intestine. By day 4 they were detectable by direct plating in all organs and the total cfu showed a significant increase on day 7. On day 14, the total cfu showed a decline but one out of three mice had died. The remaining inoculated mice died on day 16 and no more animals were available for enumeration of organ counts. When mice were inoculated i.p. with the virulent parent, the organisms were detected by direct plating on day 1 from the liver, spleen, MLN and intestine. The total number of cfu increased in these organs on day 4. By day 7 after inoculation, all but two mice were dead (table IV) . 
Immun isa t ion-challenge experiments
Immunological response
Mice immunised with either two doses of live mutant (CS405/SL5794) or three doses of formalinkilled virulent organisms by the i.p. route developed high antibody ELISA titres, whereas those immunised with one dose of live mutant organisms by the i.p. route had low antibody titres (table VI) . On the other hand, no antibody titres were detectable in mice immunised orally with one or two doses of the mutant aroA strain. Mice immunised with the live, S. serotype Bovismorbificans aroA (CS405/SL5794) by the i.p. route (one or two doses) developed a significant cutaneous hypersensitivity which was determined to be characteristic of a delayed-type hypersensitivity response (i.e., type IV cell-mediated immune response represented by a predominantly lymphocytic infiltration, determined histologically). Those immunised by the oral route or with formalin-killed virulent parent organisms did not show this response (table VI) .
Discussion
Recent experiments in our laboratory revealed that while mice immunised with S . serotype Typhimurium aroA, administered either orally or parenterally, were partially protected against experimental challenge infection with virulent S. serotype Bovismorbificans, sheep immunised orally were unprotected (Mukkur and Walker, unpublished data). Therefore, it was considered necessary to generate S. serotype Bovismorbificans aroA by genetic manipulation and to evaluate its vaccine potential in mice in the first instance. Whereas the 0-specific phage P22 has been used to transduce genes from one Salmonella strain to another within or between Groups A, B and D, the generalised transducing phase P1 was used for transduction of genes from S. serotype Typhimurium aroA made galE to S . serotype Choleraesuis (Group C1) made galE. l 1 In this investigation, this process led to the generation of aroA, galE galK and/or galT derivatives (CS404/SL5785 or 5786) which were rough. However, the aroA strain CS404/SL5785 could be made Gal' and smooth by conjunction with S . serotype Typhimurium carrying F '8-gal (SL3550). Regardless of the route used for the immunisation of mice, the rough strain (CS404/SL5785) did not impart any protection (data not shown) whereas the aroA Gal+ strain (CS405/SL5794) imparted significant parent (CS4OO/SL5747) did not develop any delayedtype hypersensitivity, whereas those immunised with the live, aroA Gal+ strain (CS405/SL5794) by the i.p. route showed a significant development. Since elicitation of delayed-type hypersensitivity is an indicator of cell-mediated immune response, the failure of the formalin-killed vaccine to impart protection against salmonellosis confirmed a role for cellular immunity in the prevention of this disease, as suggested previously. l5 However, since mice immunised by the oral route which did not develop any delayed-type hypersensitivity were also protected, an important role for the localised cellular or humoral immune factors, or both, was also indicated. Although the nature of these local protective factors is not known at the present time, similar observations were made previously in sheep immunised with S . serotype Typhimurium aroA by the oral routee6 
